source
- Incyte drops phase-1 JAK2 inhibitor to focus on next-generation candidatesIncyte announced it is abandoning its phase-1 JAK2V617F inhibitor, INCB160058, which was being tested in patients with myeloproliferative neoplasms. The decision was disclosed in the company's sec…
- WHO publishes first interim list of 12 medical device regulators eligible for WHO-listed authority statusThe World Health Organization has released its first interim list of medical device regulators that can attain WHO-listed authority status. The list names 12 regulators from different regions that…